Silverback Therapeutics (Silverback Therapeutics) Operating Cash Flow per Share : $-2.07 (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Silverback Therapeutics Operating Cash Flow per Share?

Silverback Therapeutics's operating cash flow per share for the three months ended in Sep. 2022 was $-0.47. Silverback Therapeutics's operating cash flow per share for the trailing twelve months (TTM) ended in Sep. 2022 was $-2.07.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 17.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Silverback Therapeutics's Operating Cash Flow per Share or its related term are showing as below:

SBTX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 17.9 Med: 17.9 Max: 17.9
Current: 17.9

During the past 4 years, Silverback Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 17.90% per year. The lowest was 17.90% per year. And the median was 17.90% per year.

SBTX's 3-Year OCF Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.7 vs SBTX: 17.90

Silverback Therapeutics Operating Cash Flow per Share Historical Data

The historical data trend for Silverback Therapeutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silverback Therapeutics Operating Cash Flow per Share Chart

Silverback Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Operating Cash Flow per Share

-3.45

-2.04

-10.73

-1.91

Silverback Therapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Operating Cash Flow per Share	Get a 7-Day Free Trial									-0.55	-0.61	-0.56	-0.43	-0.47

Competitive Comparison of Silverback Therapeutics's Operating Cash Flow per Share

For the Biotechnology subindustry, Silverback Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silverback Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silverback Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Silverback Therapeutics's Price-to-Operating-Cash-Flow falls into.

Silverback Therapeutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Silverback Therapeutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2021 is calculated as

Operating Cash Flow per Share (A: Dec. 2021 )	=	Cash Flow from Operations (A: Dec. 2021 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2021 )
	=	-66.76	/	34.926
	=	-1.91

Silverback Therapeutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2021 is calculated as

Operating Cash Flow per Share (Q: Sep. 2022 )	=	Cash Flow from Operations (Q: Sep. 2022 )	/	Shares Outstanding (Diluted Average) (Q: Sep. 2022 )
	=	-16.58	/	35.458
	=	-0.47

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.07

Silverback Therapeutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Silverback Therapeutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Silverback Therapeutics (Silverback Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silverback Therapeutics Inc (NAS:SBTX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Fairview Avenue N, Suite 600, Seattle, WA, USA, 98109

Website

https://www.silverbacktx.com

Silverback Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on leveraging its ImmunoTAC technology platform to develop tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases.

Executives

Brian Dorsey	officer: Chief Operating Officer	C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Alexander A Fitzpatrick	officer: Chief Legal Officer	9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Pratik Shah Living Trust Dated June 15, 2011	10 percent owner	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Michael Kelly	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Rajeev Dadoo	director	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Sarina Tanimoto	10 percent owner, officer: Chief Medical Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Eric Karas	officer: Chief Commercial Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma	officer: Chief Business Officer	C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal	director, 10 percent owner, officer: President and CEO	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Pratik Shah	director, 10 percent owner	3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Ra Capital Nexus Fund Ii, L.p.	director	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kathleen D. Scott	officer: Chief Financial Officer	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Deerfield Mgmt Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Private Design Fund Iv, L.p.	director, 10 percent owner, other: * Director by deputization	780 THIRD AVENUE 37TH FLOOR, NEW YORK NY 10017